Annable T - Search Results

1

2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.

Wissner A, Floyd MB, Johnson BD, Fraser H, Ingalls C, Nittoli T, Dushin RG, Discafani C, Nilakantan R, Marini J, Ravi M, Cheung K, Tan X, Musto S, Annable T, Siegel MM, Loganzo F. Wissner A, et al. Among authors: annable t. J Med Chem. 2005 Dec 1;48(24):7560-81. doi: 10.1021/jm050559f. J Med Chem. 2005. PMID: 16302797

2

Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment.

Yamashita A, Norton EB, Kaplan JA, Niu C, Loganzo F, Hernandez R, Beyer CF, Annable T, Musto S, Discafani C, Zask A, Ayral-Kaloustian S. Yamashita A, et al. Among authors: annable t. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5317-22. doi: 10.1016/j.bmcl.2004.08.024. Bioorg Med Chem Lett. 2004. PMID: 15454219

3

Synthesis and biological activity of analogues of the antimicrotubule agent N,beta,beta-trimethyl-L-phenylalanyl-N(1)-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]- N(1),3-dimethyl-L-valinamide (HTI-286).

Zask A, Birnberg G, Cheung K, Kaplan J, Niu C, Norton E, Suayan R, Yamashita A, Cole D, Tang Z, Krishnamurthy G, Williamson R, Khafizova G, Musto S, Hernandez R, Annable T, Yang X, Discafani C, Beyer C, Greenberger LM, Loganzo F, Ayral-Kaloustian S. Zask A, et al. Among authors: annable t. J Med Chem. 2004 Sep 9;47(19):4774-86. doi: 10.1021/jm040056u. J Med Chem. 2004. PMID: 15341492

4

HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.

Loganzo F, Discafani CM, Annable T, Beyer C, Musto S, Hari M, Tan X, Hardy C, Hernandez R, Baxter M, Singanallore T, Khafizova G, Poruchynsky MS, Fojo T, Nieman JA, Ayral-Kaloustian S, Zask A, Andersen RJ, Greenberger LM. Loganzo F, et al. Among authors: annable t. Cancer Res. 2003 Apr 15;63(8):1838-45. Cancer Res. 2003. PMID: 12702571

5

MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.

Sampath D, Discafani CM, Loganzo F, Beyer C, Liu H, Tan X, Musto S, Annable T, Gallagher P, Rios C, Greenberger LM. Sampath D, et al. Among authors: annable t. Mol Cancer Ther. 2003 Sep;2(9):873-84. Mol Cancer Ther. 2003. PMID: 14555706

6

Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.

Hari M, Loganzo F, Annable T, Tan X, Musto S, Morilla DB, Nettles JH, Snyder JP, Greenberger LM. Hari M, et al. Among authors: annable t. Mol Cancer Ther. 2006 Feb;5(2):270-8. doi: 10.1158/1535-7163.MCT-05-0190. Mol Cancer Ther. 2006. PMID: 16505100

7

Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.

Loganzo F, Hari M, Annable T, Tan X, Morilla DB, Musto S, Zask A, Kaplan J, Minnick AA Jr, May MK, Ayral-Kaloustian S, Poruchynsky MS, Fojo T, Greenberger LM. Loganzo F, et al. Among authors: annable t. Mol Cancer Ther. 2004 Oct;3(10):1319-27. Mol Cancer Ther. 2004. PMID: 15486199

8

Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.

Poruchynsky MS, Kim JH, Nogales E, Annable T, Loganzo F, Greenberger LM, Sackett DL, Fojo T. Poruchynsky MS, et al. Among authors: annable t. Biochemistry. 2004 Nov 9;43(44):13944-54. doi: 10.1021/bi049300+. Biochemistry. 2004. PMID: 15518543

9

Alpha-mercaptoketone based histone deacetylase inhibitors.

Wash PL, Hoffman TZ, Wiley BM, Bonnefous C, Smith ND, Sertic MS, Lawrence CM, Symons KT, Nguyen PM, Lustig KD, Guo X, Annable T, Noble SA, Hager JH, Hassig CA, Malecha JW. Wash PL, et al. Among authors: annable t. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6482-5. doi: 10.1016/j.bmcl.2008.10.058. Epub 2008 Oct 17. Bioorg Med Chem Lett. 2008. PMID: 18954984

10

A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.

Greenberger LM, Annable T, Collins KI, Komm BS, Lyttle CR, Miller CP, Satyaswaroop PG, Zhang Y, Frost P. Greenberger LM, et al. Among authors: annable t. Clin Cancer Res. 2001 Oct;7(10):3166-77. Clin Cancer Res. 2001. PMID: 11595711

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters